Dr. Park on Potential Alternate CAR T-Cell Targets in B-Cell Malignancies

Video

Jae H.Park, MD, discusses potential alternate CAR T-cell targets in B-cell malignancies.

Jae H. Park, MD, attending physician, Leukemia Service and Cellular Therapeutics Center, Memorial Sloan Kettering Cancer Center, discusses potential alternate CAR T-cell targets in B-cell malignancies.

Though significant response rates have been demonstrated with CD19-targeting CAR T-cells, investigation into other possible B-cell antigen targets are ongoing, says Park. CD22 is of particular interest, though responses do not appear as durable as those seen with CD19-targeting antigens.

Additionally, dual-targeting CAR T-cell therapy may increase response rates in this field. At the 2019 ASH Annual Meeting, an update from a phase I dose-climbing study (ChiCTR1800018143) showed objective response rates of over 90% was shown with CAR T-cells targeting both CD38 and BCMA in patients with extramedullary multiple myeloma.

Related Videos
Sowmya Viswanathan, PhD, on Translating Cell Therapies to the Clinic at ISCT 2024
Omar Nadeem, MD, on Initial Efficacy of GPRC5D-CAR in R/R Multiple Myeloma
Omer A. Abdul Hamid, MD, on Improving Gene Therapy’s Effect and Accessibility
George Tachas, PhD, on Tackling DMD Treatment From Multiple Angles
David Suhy, PhD, the cofounder and chief scientific officer of Earli
Deepak L. Bhatt, MD, MPH, MBA, on Incorporating AI into Genetic Research for Cardiovascular Disease
Jeffrey Chamberlain, PhD, on Helping Progress Cell and Gene Therapy Development
Jonathan W. Weinsaft, MD, on Integrating Genetic Research into Cardiovascular Medicine
Jacques Galipeau, MD, on Highlights from ISCT 2024’s Presidential Plenary
Vanee Pho, PhD, the senior director of product management, cell and gene therapy, at Mission Bio
© 2024 MJH Life Sciences

All rights reserved.